ERG and prostate carcinoma: In contrast the other major HES6 antagonist HES1 (Bae et al. 2000, Hatakeyama et al. 2004, 2006, Jacobsen et al. 2008) showed a strong positive correlation with ERG expression (r=0.65; Fig. 3h), suggesting an ERG–HES1–HES6 transcriptional network in ERG-fusion positive prostate cancer cells (Fig. 3g, h and i).